ArcticZymes Technologies ASA
B4V
Company Profile
Business description
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
Contact
Sykehusveien 23
Tromso9294
NORT: +47 77648900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
7 undervalued US stocks that crushed earnings
Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued ASX share hitting on all cylinders
Strong performance across all segments in latest earnings release.
stocks
Investor Playbook: Can your portfolio handle what’s next?
Testing portfolio resilience in an uncertain market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,193.90 | 10.60 | -0.12% |
| CAC 40 | 8,368.91 | 7.55 | 0.09% |
| DAX 40 | 26,749.95 | 21.93 | -0.08% |
| Dow JONES (US) | 52,347.55 | 50.46 | 0.10% |
| FTSE 100 | 10,902.56 | 39.47 | 0.36% |
| HKSE | 23,787.51 | 149.91 | 0.63% |
| NASDAQ | 25,136.27 | 229.82 | -0.91% |
| Nikkei 225 | 60,218.42 | 923.93 | -1.51% |
| NZX 50 Index | 14,252.58 | 78.90 | 0.56% |
| S&P 500 | 7,561.67 | 30.73 | -0.40% |
| S&P/ASX 200 | 9,073.00 | 9.20 | -0.10% |
| SSE Composite Index | 3,599.70 | 34.65 | -0.95% |